Citigroup Inc Dexcom Inc Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$64.0 - $116.06 $1.79 Million - $3.25 Million	-28,000 Reduced 21.24%	103,800 $6.96 Million
Q2 2024 Aug 12, 2024	BUY	$110.31 - $140.45 $7.5 Million - $9.55 Million	68,000 Added 106.58%	131,800 $14.9 Million
Q3 2023 Nov 09, 2023	SELL	$86.06 - $137.93 $2.14 Million - $3.43 Million	-24,900 Reduced 28.07%	63,800 $5.95 Million
Q2 2023 Aug 10, 2023	BUY	$112.47 - $130.98 $9.75 Million - $11.4 Million	86,700 Added 4335.0%	88,700 $11.4 Million
Q1 2023 May 11, 2023	SELL	$104.0 - $122.92 $4.99 Million - $5.9 Million	-48,000 Reduced 96.0%	2,000 $232,000
Q4 2022 Feb 09, 2023	BUY	$84.98 - $122.67 $4.25 Million - $6.13 Million	50,000 New	50,000 $5.66 Million

1,013

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $29.3B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.